{
    "id": 571,
    "fullName": "TP53 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TP53 loss indicates loss of the TP53 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "loss",
    "createDate": "05/14/2014",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8588,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 2844,
                "therapyName": "BLZ945",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6692,
                    "pubMedId": 27199435,
                    "title": "The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27199435"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4445,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in cisplatin-resistant ovarian cancer cells with TP53 loss in culture and in xenograft models (PMID: 25376608).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3515,
                "therapyName": "Cisplatin + LB-100",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4553,
                    "pubMedId": 25376608,
                    "title": "The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25376608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13543,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 2325,
                "therapyName": "Idelalisib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4205,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4435,
                    "pubMedId": 21980130,
                    "title": "Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21980130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 233,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 979,
                "therapyName": "Ad5CMV-p53 gene",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 162,
                    "pubMedId": 15608394,
                    "title": "In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15608394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4645,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18934,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Copiktra (duvelisib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1024,
                "therapyName": "Duvelisib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20083,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Calquence (acalabrutinib) combined with Gazyva (obinutuzumab) is indicated in the guidelines as first-line therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3477,
                "therapyName": "Acalabrutinib + Obinutuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16497,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had a rapid response to combined Rituxan (rituximab) and Imbruvica (ibrutinib) therapy, achieved a complete remission (CR) within 6 months, underwent autologous stem-cell transplantation, and remained in CR 18 months thereafter (PMID: 30559058).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3280,
                "therapyName": "Ibrutinib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14568,
                    "pubMedId": 30559058,
                    "title": "Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30559058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16494,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had no response to combined Rituxan (rituximab) and Treanda (bendamustine) therapy, and had a doubling of white blood cells during two cycles of treatment (PMID: 30559058).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 2323,
                "therapyName": "Bendamustine + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14568,
                    "pubMedId": 30559058,
                    "title": "Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30559058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4085,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3366,
                "therapyName": "SP600125",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4399,
                    "pubMedId": 22438244,
                    "title": "Selective killing of p53-deficient cancer cells by SP600125.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22438244"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALRN-6924 did not inhibit the growth of TP53-null acute myeloid leukemia cells in culture (PMID: 29643228).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11462,
                    "pubMedId": 29643228,
                    "title": "Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29643228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13545,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Venclexta (venetoclax) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12228,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a thymoma cell line with TP53 loss demonstrated primary resistance to Selinexor (KPT-330) in culture, and reconstitution of TP53 expression resulted in increased Selinexor sensitivity (PMID: 28819023).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 3275,
                "name": "thymoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10184,
                    "pubMedId": 28819023,
                    "title": "Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28819023"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line deficient in TP53 demonstrated increased sensitivity to sequential treatment with SN-38 and CHIR-124 compared to cells with wild-type TP53, resulting in increased apoptosis and micronucleation in culture (PMID: 17255282).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 6628,
                "therapyName": "CHIR-124 + SN-38",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10687,
                    "pubMedId": 17255282,
                    "title": "CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17255282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8255,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53-null lung cancer cells were resistant to KRT-232 (AMG 232) induced growth inhibition in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18929,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Venclexta (venetoclax) and Gazyva (obinutuzumab) is indicated in the guidelines as first line therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3636,
                "therapyName": "Obinutuzumab + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13539,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Imbruvica (ibrutinib) is indicated in the guidelines as first line therapy and relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4647,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 403,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Gemzar (gemcitabine) inhibited Wee1 expression, Cdc2 phosphorylation, and tumor growth in several patient-derived xenograft models of pancreatic cancer harboring TP53 mutations (PMID: 21389100).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1279,
                "therapyName": "Adavosertib + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 50,
                    "pubMedId": 21389100,
                    "title": "MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21389100"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1123,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon Adavosertib (MK-1775) administration (PMID: 19887545).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 874,
                    "pubMedId": 19887545,
                    "title": "Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19887545"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5771,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18926,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "Loss of TP53 is associated with a poor prognosis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10393,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 5503,
                "therapyName": "PHA-680632 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8415,
                    "pubMedId": 18026198,
                    "title": "Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18026198"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13541,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Venclexta (venetoclax) combined with Rituxan (rituximab) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3937,
                "therapyName": "Rituximab + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18932,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Calquence (acalabrutinib) is indicated in the guidelines as relapsed/refractory therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 1605,
                "therapyName": "Acalabrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 6354,
                "name": "CLL/SLL",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4273,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3406,
                "therapyName": "ReACp53",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4309,
                    "pubMedId": 26748848,
                    "title": "A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26748848"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5571,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3899,
                "therapyName": "CTX-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8261,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10018,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 increased sensitivity to radiotherapy in colorectal cancer xenograft models harboring a loss of TP53, resulting in a greater delay of tumor growth compared to radiation alone and an improved survival compared to control or either agent alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1622,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 (PRIMA1-MET) treatment of Tp53-null lung adenocarcinoma cells expressing mutant Tp63 resulted in Tp63-dependent increase in apoptosis, increased Tp63 target gene expression, and redistribution of Tp63 in cell culture (PMID: 20818419).",
            "molecularProfile": {
                "id": 2779,
                "profileName": "TP53 loss TP63 inact mut"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1743,
                    "pubMedId": 20818419,
                    "title": "PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20818419"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 (PRIMA1-MET) treatment of Tp53-null lung adenocarcinoma cells expressing a Tp73 inactivating mutation resulted in Tp73-dependent growth suppression and apoptosis in cell culture (PMID: 20818419).",
            "molecularProfile": {
                "id": 2782,
                "profileName": "TP53 loss TP73 inact mut"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1743,
                    "pubMedId": 20818419,
                    "title": "PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20818419"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2016,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).",
            "molecularProfile": {
                "id": 4728,
                "profileName": "BRCA1 C61G TP53 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2497,
                    "pubMedId": 22172724,
                    "title": "BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22172724"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4552,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7762 enhanced sensitivity to Gemzar (gemcitabine) in bladder cancer cell lines harboring CDKN1A loss and TP53 loss, resulting in decreased cell growth in culture (PMID: 25349305).",
            "molecularProfile": {
                "id": 17584,
                "profileName": "CDKN1A loss TP53 loss"
            },
            "therapy": {
                "id": 1968,
                "therapyName": "AZD7762 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4471,
                    "pubMedId": 25349305,
                    "title": "Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349305"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4551,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-00477736 enhanced sensitivity to Gemzar (gemcitabine) in bladder cancer cell lines harboring CDKN1A loss and TP53 loss, resulting in decreased tumor growth in xenograft models (PMID: 25349305).",
            "molecularProfile": {
                "id": 17584,
                "profileName": "CDKN1A loss TP53 loss"
            },
            "therapy": {
                "id": 3466,
                "therapyName": "Gemcitabine + PF-00477736",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4471,
                    "pubMedId": 25349305,
                    "title": "Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349305"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line with loss of TP53, MYCN over expression, and harboring DDR2 L63V demonstrated greater inhibition of tumor growth in xenograft models when treated with the combination of Sprycel (dasatinib) and JQ1 compared to either therapy alone (PMID: 26206333).",
            "molecularProfile": {
                "id": 20483,
                "profileName": "DDR2 L63V MYCN over exp TP53 loss"
            },
            "therapy": {
                "id": 3824,
                "therapyName": "Dasatinib + JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5000,
                    "pubMedId": 26206333,
                    "title": "NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26206333"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7252,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ama-HEA125 inhibited tumor growth in animal models of colorectal cancer harboring concomitant POLR2A and TP53 loss (PMID: 25901683).",
            "molecularProfile": {
                "id": 24808,
                "profileName": "POLR2A loss TP53 loss"
            },
            "therapy": {
                "id": 3457,
                "therapyName": "Ama-HEA125",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4431,
                    "pubMedId": 25901683,
                    "title": "TP53 loss creates therapeutic vulnerability in\u00a0colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25901683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8945,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer model lacking both BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455).",
            "molecularProfile": {
                "id": 26544,
                "profileName": "BRCA1 loss TP53 loss"
            },
            "therapy": {
                "id": 2542,
                "therapyName": "AZD2461",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6793,
                    "pubMedId": 27550455,
                    "title": "The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550455"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alisertib (MLN8237) enhanced the sensitivity of Platinol (cisplatin) combined with Vepesid (etoposide) in small cell lung cancer mouse models expressing MYC T58A and loss of TP53 and RB1, resulting in complete tumor growth inhibition, stable disease in 62.5% (10/16), and decreased tumor volume by 30% in three of the mice (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 5257,
                "therapyName": "Alisertib + Cisplatin + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Alisertib (MLN8237) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, small cell lung cancer mouse cells expressing MYC T58A and loss of RB1 and TP53 demonstrated sensitivity to Barasertib (AZD1152) in culture, resulting in inhibition of cell growth (PMID: 28089889).",
            "molecularProfile": {
                "id": 27138,
                "profileName": "MYC T58A RB1 loss TP53 loss"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7676,
                    "pubMedId": 28089889,
                    "title": "MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28089889"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10437,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",
            "molecularProfile": {
                "id": 27462,
                "profileName": "ALK rearrange RB1 C706F TP53 loss"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8449,
                    "pubMedId": 28285684,
                    "title": "Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28285684"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10888,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).",
            "molecularProfile": {
                "id": 27832,
                "profileName": "PTEN loss TP53 loss"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8893,
                    "pubMedId": 26910118,
                    "title": "Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26910118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",
            "molecularProfile": {
                "id": 28317,
                "profileName": "KRAS mut STK11 loss TP53 loss"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13987,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in leiomyosarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053).",
            "molecularProfile": {
                "id": 29900,
                "profileName": "MDM2 amp TP53 loss"
            },
            "therapy": {
                "id": 2113,
                "therapyName": "GDC-0575 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11402,
                    "pubMedId": 29409053,
                    "title": "CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16378,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E709_T710delinsD who progressed after a 1 year partial response to Gilotrif (afatinib) was found to have disease that transformed to small cell lung cancer and had acquired a SMAD4 R361C mutation and did not express Tp53 protein (PMID: 30413663).",
            "molecularProfile": {
                "id": 31618,
                "profileName": "EGFR E709_T710delinsD SMAD4 R361C TP53 loss"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14466,
                    "pubMedId": 30413663,
                    "title": "SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30413663"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 630,
            "profileName": "TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2779,
            "profileName": "TP53 loss TP63 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2782,
            "profileName": "TP53 loss TP73 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4728,
            "profileName": "BRCA1 C61G TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17584,
            "profileName": "CDKN1A loss TP53 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 7619,
                    "name": "Gemcitabine + PF-00477736",
                    "profileName": "CDKN1A loss TP53 loss"
                },
                {
                    "id": 7620,
                    "name": "AZD7762 + Gemcitabine",
                    "profileName": "CDKN1A loss TP53 loss"
                }
            ]
        },
        {
            "id": 20483,
            "profileName": "DDR2 L63V MYCN over exp TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24808,
            "profileName": "POLR2A loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26544,
            "profileName": "BRCA1 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27138,
            "profileName": "MYC T58A RB1 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27462,
            "profileName": "ALK rearrange RB1 C706F TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27832,
            "profileName": "PTEN loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28317,
            "profileName": "KRAS mut STK11 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29900,
            "profileName": "MDM2 amp TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31618,
            "profileName": "EGFR E709_T710delinsD SMAD4 R361C TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}